TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01621997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: operation inspection
Description: Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: operation inspection
Description: Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: operation inspection
Description: Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months
Study: NCT01938131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated Muscle Vibration (rMV) (Cro ® System)
Description: The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
Study: NCT04163900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-1031
Description: IV infusion in 500 mL of 0.9% sterile saline for injection given over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion in 250 mL of 0.9% sterile saline for injection given in accordance with the package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV in accordance with local institutional practice for biliary tract cancer, including the use of an appropriate hydration protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV in accordance with local institutional practice for biliary tract cancer, including the use of an appropriate hydration protocol
Study: NCT03608267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: The jejunum between the two loops is sutered with Endomina and cut 15 days later.
Study: NCT01086410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Powder
Description: Placebo Inhalation powder inhaled once daily for 6 weeks' treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder
Description: Placebo Inhalation powder inhaled once daily for 6 weeks' treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder
Description: Dose B inhaled once daily for 6 weeks' treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder
Description: Dose A inhaled once daily for 6 weeks' treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Description: One placebo capsule taken each day on the last 7 days of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule
Description: One placebo capsule taken each day on the last 7 days of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: One placebo capsule taken each day on the last 7 days of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Oral Capsule
Description: Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
Study: NCT03560947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercise (Physiotherapy Intervention)
Description: Experimental group: Manual Therapy and Exercise Participants in this group will receive a 6-weeks program of mobilization and progressive exercise programme for the neck flexors, 2 times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (Physiotherapy Intervention)
Description: Active Comparator: Usual Care Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
Study: NCT00003370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irofulven
Study: NCT00419120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous neo bladder construct
Description: augmentation cystoplasty with autologous neo-bladder construct
Study: NCT02079090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol
Description: 0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentofol
Description: 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
Study: NCT03809455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate
Description: Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge...), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one intake of placebo (intranasal or buccal)
Study: NCT01942148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT03901573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle
Study: NCT00857532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Study: NCT03653104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melodica Intervention
Description: The melodica program will include education about pursed lip breathing, instruction in the melodica instrument, and participation in a melodica training group which meets twice-weekly for an 8-week period. Each session will include musical instruction, group music-making, and education about COPD and related health topics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Health Education
Description: A single session including education about COPD and related health topics.
Study: NCT05359991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
Study: NCT01903642

Intervention type: OTHER
Group type: OTHER
Intervention: proteomic analysis
Study: NCT01546974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HME filter Twin Star 55, Drager Medical, Germany

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated humidification
Study: NCT01641237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluoride
Description: fluoride as sodium fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluoride
Description: fluoride as sodium fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluoride
Description: fluoride as sodium fluoride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no added fluoride in a silica base
Description: no added fluoride
Study: NCT04678596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EonAligner
Description: EonAligner system is one stage system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearfix
Description: Clearfix system is three-stage system.
Study: NCT06228651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The leg without the tourniquet
Study: NCT04127825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution (ANH)
Description: Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
Study: NCT02825004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Study: NCT04549727

Intervention type: OTHER
Intervention: Organoids creation
Description: Organoids are created from discarded tissue

Intervention type: OTHER
Intervention: Organoids creation
Description: Organoids are created from discarded tissue
Study: NCT00286481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and simvastatin
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and simvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Study: NCT00909181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Study: NCT02336789

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fecal material
Description: . All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
Study: NCT04573751

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine + verapamil
Description: Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study: NCT05368961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Distraction (interactive tablet)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Anxiolytic ordered by anesthesiologist is usual care
Study: NCT05197517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg
Description: Film Coated Tablets products containing 10 mg Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Description: Film Coated Tablets products containing 10 mg Rosuvastatin
Study: NCT02908425

Intervention type: OTHER
Group type: OTHER
Intervention: Statin user
Description: Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
Study: NCT00127868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
Study: NCT00408330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic Acid 15% Gel
Description: 15% gel, topically applied daily for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive 15% gel base
Description: placebo, topically applied daily for six weeks
Study: NCT00862303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2/IFN-α
Description: Patients receive treatment of IL-2 or IFN-α.
Study: NCT02560064

Intervention type: PROCEDURE
Intervention: Laparotomy
Description: Small bowel length will measure in laparotomy, regardless of indication.
Study: NCT03148678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Subjects are provided with smartphone-based mindfulness intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindfulness
Description: Subjects are provided with smartphone-based mindfulness intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Subjects are provided with smartphone-based mindfulness intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindfulness
Description: Subjects are provided with smartphone-based mindfulness intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contingent RT-fMRI-NF
Description: Subjects are provided with contingent RT-fMRI-NF of their own brain activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contingent RT-fMRI-NF
Description: Subjects are provided with contingent RT-fMRI-NF of their own brain activity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham RT-fMRI-NF
Description: Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham RT-fMRI-NF
Description: Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Wandering
Description: Subjects are provided with smartphone-based mind wandering intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mind Wandering
Description: Subjects are provided with smartphone-based mind wandering intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Wandering
Description: Subjects are provided with smartphone-based mind wandering intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mind Wandering
Description: Subjects are provided with smartphone-based mind wandering intervention.
Study: NCT04216186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q
Description: Coenzyme Q once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q
Description: Coenzyme Q once daily
Study: NCT01383161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six capsules per day for 18 months.
Study: NCT03099239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCT-MSC infusion
Description: hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCT-MSC infusion
Description: hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCT-MSC infusion
Description: hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
Study: NCT03706404

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-Care ultrasound and testing
Description: Point-of-Care ultrasound + Point-of-Care blood gas testing
Study: NCT02675023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M923
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M923
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Study: NCT04440787

Intervention type: PROCEDURE
Intervention: Three point cuff palpation technique
Description: the ETT is finally positioned according to the Three point cuff technique.
Study: NCT03575078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ761, Olaparib
Description: ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
Study: NCT00068588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally